APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chagas Disease Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Chagas Disease Drug Industry Growth and Trends Forecast to 2032

22 December 2025103 pages

Choose your research edition.

Industry ResearchChagas Disease Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Chagas Disease Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Chagas Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chagas Disease Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Chagas Disease Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Chagas Disease Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Chagas Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Chagas Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chagas Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chagas Disease Drug include Eisai Co Ltd, Sanofi, Novartis AG, GlaxoSmithKline Plc, Bayer AG, AstraZeneca Plc, Oblita Therapeutics BVBA, Merck & Co Inc and Kancera AB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Chagas Disease Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Chagas Disease Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Chagas Disease Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Chagas Disease Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Chagas Disease Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Chagas Disease Drug Market by Company

Eisai Co Ltd

Sanofi

Novartis AG

GlaxoSmithKline Plc

Bayer AG

AstraZeneca Plc

Oblita Therapeutics BVBA

Merck & Co Inc

Kancera AB

Humanigen Inc

Grupo Praxis Pharmaceutical SA

Daiichi Sankyo Co Ltd

Chagas Disease Drug Segment by Type

Cz-007

Cz-008

D-121

DNDI-0690

EPLBS-1246

EPLBS-967

Others

Chagas Disease Drug Segment by Application

Hospital

Clinic

Others

Chagas Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chagas Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chagas Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chagas Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chagas Disease Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Chagas Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Cz-007 Table 2. Major Company of Cz-008 Table 3. Major Company of D-121 Table 4. Major Company of DNDI-0690 Table 5. Major Company of EPLBS-1246 Table 6. Major Company of EPLBS-967 Table 7. Major Company of Others Table 8. Global Chagas Disease Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 9. Global Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 10. Global Chagas Disease Drug Sales Market Share in Volume by Type (2021-2026) Table 11. Global Chagas Disease Drug Sales by Type (2021-2026) & (US$ Million) Table 12. Global Chagas Disease Drug Sales Market Share in Value by Type (2021-2026) Table 13. Global Chagas Disease Drug Price by Type (2021-2026) & (US$/unit) Table 14. Global Chagas Disease Drug Sales by Type (2027-2032) & (k units) Table 15. Global Chagas Disease Drug Sales Market Share in Volume by Type (2027-2032) Table 16. Global Chagas Disease Drug Sales by Type (2027-2032) & (US$ Million) Table 17. Global Chagas Disease Drug Sales Market Share in Value by Type (2027-2032) Table 18. Global Chagas Disease Drug Price by Type (2027-2032) & (US$/unit) Table 19. North America Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 20. North America Chagas Disease Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Europe Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 22. Europe Chagas Disease Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Asia-Pacific Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 24. Asia-Pacific Chagas Disease Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Latin America Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 26. Latin America Chagas Disease Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Middle East and Africa Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 28. Middle East and Africa Chagas Disease Drug Sales by Type (2021-2026) & (US$ Million) Table 29. Chagas Disease Drug Industry Trends Table 30. Chagas Disease Drug Industry Drivers Table 31. Chagas Disease Drug Industry Opportunities and Challenges Table 32. Chagas Disease Drug Industry Restraints Table 33. Global Chagas Disease Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 34. Global Chagas Disease Drug Revenue Market Share by Company (2021-2026) Table 35. Global Chagas Disease Drug Sales by Company (2021-2026) & (k units) Table 36. Global Chagas Disease Drug Sales Share by Company (2021-2026) Table 37. Global Chagas Disease Drug Market Price by Company (2021-2026) & (US$/unit) Table 38. Global Chagas Disease Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 39. Global Chagas Disease Drug Major Company Production Sites and Headquarters Table 40. Global Chagas Disease Drug Company, Product Type & Application Table 41. Global Chagas Disease Drug Company Establishment Date Table 42. Global Company Market Concentration Ratio (CR5 and HHI) Table 43. Global Chagas Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 44. Global Chagas Disease Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 45. Global Chagas Disease Drug Sales by Region (2021-2026) & (k units) Table 46. Global Chagas Disease Drug Sales Market Share in Volume by Region (2021-2026) Table 47. Global Chagas Disease Drug Sales by Region (2021-2026) & (US$ Million) Table 48. Global Chagas Disease Drug Sales Market Share in Value by Region (2021-2026) Table 49. Global Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 50. Global Chagas Disease Drug Sales by Region (2027-2032) & (k units) Table 51. Global Chagas Disease Drug Sales Market Share in Volume by Region (2027-2032) Table 52. Global Chagas Disease Drug Sales by Region (2027-2032) & (US$ Million) Table 53. Global Chagas Disease Drug Sales Market Share in Value by Region (2027-2032) Table 54. Global Chagas Disease Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 55. Global Chagas Disease Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 56. Global Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 57. Global Chagas Disease Drug Sales Market Share in Volume by Application (2021-2026) Table 58. Global Chagas Disease Drug Sales by Application (2021-2026) & (US$ Million) Table 59. Global Chagas Disease Drug Sales Market Share in Value by Application (2021-2026) Table 60. Global Chagas Disease Drug Price by Application (2021-2026) & (US$/unit) Table 61. Global Chagas Disease Drug Sales by Application (2027-2032) & (k units) Table 62. Global Chagas Disease Drug Sales Market Share in Volume by Application (2027-2032) Table 63. Global Chagas Disease Drug Sales by Application (2027-2032) & (US$ Million) Table 64. Global Chagas Disease Drug Sales Market Share in Value by Application (2027-2032) Table 65. Global Chagas Disease Drug Price by Application (2027-2032) & (US$/unit) Table 66. North America Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 67. North America Chagas Disease Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Europe Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 69. Europe Chagas Disease Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Asia-Pacific Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 71. Asia-Pacific Chagas Disease Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Latin America Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 73. Latin America Chagas Disease Drug Sales by Application (2021-2026) & (US$ Million) Table 74. Middle East and Africa Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 75. Middle East and Africa Chagas Disease Drug Sales by Application (2021-2026) & (US$ Million) Table 76. Eisai Co Ltd Company Information Table 77. Eisai Co Ltd Business Overview Table 78. Eisai Co Ltd Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Eisai Co Ltd Chagas Disease Drug Product Portfolio Table 80. Eisai Co Ltd Recent Development Table 81. Sanofi Company Information Table 82. Sanofi Business Overview Table 83. Sanofi Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Sanofi Chagas Disease Drug Product Portfolio Table 85. Sanofi Recent Development Table 86. Novartis AG Company Information Table 87. Novartis AG Business Overview Table 88. Novartis AG Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Novartis AG Chagas Disease Drug Product Portfolio Table 90. Novartis AG Recent Development Table 91. GlaxoSmithKline Plc Company Information Table 92. GlaxoSmithKline Plc Business Overview Table 93. GlaxoSmithKline Plc Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. GlaxoSmithKline Plc Chagas Disease Drug Product Portfolio Table 95. GlaxoSmithKline Plc Recent Development Table 96. Bayer AG Company Information Table 97. Bayer AG Business Overview Table 98. Bayer AG Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Bayer AG Chagas Disease Drug Product Portfolio Table 100. Bayer AG Recent Development Table 101. AstraZeneca Plc Company Information Table 102. AstraZeneca Plc Business Overview Table 103. AstraZeneca Plc Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. AstraZeneca Plc Chagas Disease Drug Product Portfolio Table 105. AstraZeneca Plc Recent Development Table 106. Oblita Therapeutics BVBA Company Information Table 107. Oblita Therapeutics BVBA Business Overview Table 108. Oblita Therapeutics BVBA Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Oblita Therapeutics BVBA Chagas Disease Drug Product Portfolio Table 110. Oblita Therapeutics BVBA Recent Development Table 111. Merck & Co Inc Company Information Table 112. Merck & Co Inc Business Overview Table 113. Merck & Co Inc Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Merck & Co Inc Chagas Disease Drug Product Portfolio Table 115. Merck & Co Inc Recent Development Table 116. Kancera AB Company Information Table 117. Kancera AB Business Overview Table 118. Kancera AB Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Kancera AB Chagas Disease Drug Product Portfolio Table 120. Kancera AB Recent Development Table 121. Humanigen Inc Company Information Table 122. Humanigen Inc Business Overview Table 123. Humanigen Inc Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Humanigen Inc Chagas Disease Drug Product Portfolio Table 125. Humanigen Inc Recent Development Table 126. Grupo Praxis Pharmaceutical SA Company Information Table 127. Grupo Praxis Pharmaceutical SA Business Overview Table 128. Grupo Praxis Pharmaceutical SA Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Grupo Praxis Pharmaceutical SA Chagas Disease Drug Product Portfolio Table 130. Grupo Praxis Pharmaceutical SA Recent Development Table 131. Daiichi Sankyo Co Ltd Company Information Table 132. Daiichi Sankyo Co Ltd Business Overview Table 133. Daiichi Sankyo Co Ltd Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Daiichi Sankyo Co Ltd Chagas Disease Drug Product Portfolio Table 135. Daiichi Sankyo Co Ltd Recent Development Table 136. North America Chagas Disease Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 137. North America Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 138. North America Chagas Disease Drug Sales Market Share by Country (2021-2026) Table 139. North America Chagas Disease Drug Sales Forecast by Country (2027-2032) & (k units) Table 140. North America Chagas Disease Drug Sales Market Share Forecast by Country (2027-2032) Table 141. North America Chagas Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. North America Chagas Disease Drug Market Size by Country (2021-2026) & (US$ Million) Table 143. North America Chagas Disease Drug Market Share by Country (2021-2026) Table 144. North America Chagas Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. North America Chagas Disease Drug Market Share Forecast by Country (2027-2032) Table 146. Europe Chagas Disease Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 147. Europe Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 148. Europe Chagas Disease Drug Sales Market Share by Country (2021-2026) Table 149. Europe Chagas Disease Drug Sales Forecast by Country (2027-2032) & (k units) Table 150. Europe Chagas Disease Drug Sales Market Share Forecast by Country (2027-2032) Table 151. Europe Chagas Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Europe Chagas Disease Drug Market Size by Country (2021-2026) & (US$ Million) Table 153. Europe Chagas Disease Drug Market Share by Country (2021-2026) Table 154. Europe Chagas Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Europe Chagas Disease Drug Market Share Forecast by Country (2027-2032) Table 156. Asia-Pacific Chagas Disease Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 157. Asia-Pacific Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 158. Asia-Pacific Chagas Disease Drug Sales Market Share by Country (2021-2026) Table 159. Asia-Pacific Chagas Disease Drug Sales Forecast by Country (2027-2032) & (k units) Table 160. Asia-Pacific Chagas Disease Drug Sales Market Share Forecast by Country (2027-2032) Table 161. Asia-Pacific Chagas Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Asia-Pacific Chagas Disease Drug Market Size by Country (2021-2026) & (US$ Million) Table 163. Asia-Pacific Chagas Disease Drug Market Share by Country (2021-2026) Table 164. Asia-Pacific Chagas Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Asia-Pacific Chagas Disease Drug Market Share Forecast by Country (2027-2032) Table 166. Latin America Chagas Disease Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 167. Latin America Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 168. Latin America Chagas Disease Drug Sales Market Share by Country (2021-2026) Table 169. Latin America Chagas Disease Drug Sales Forecast by Country (2027-2032) & (k units) Table 170. Latin America Chagas Disease Drug Sales Market Share Forecast by Country (2027-2032) Table 171. Latin America Chagas Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Latin America Chagas Disease Drug Market Size by Country (2021-2026) & (US$ Million) Table 173. Latin America Chagas Disease Drug Market Share by Country (2021-2026) Table 174. Latin America Chagas Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Latin America Chagas Disease Drug Market Share Forecast by Country (2027-2032) Table 176. Middle East and Africa Chagas Disease Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 177. Middle East and Africa Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 178. Middle East and Africa Chagas Disease Drug Sales Market Share by Country (2021-2026) Table 179. Middle East and Africa Chagas Disease Drug Sales Forecast by Country (2027-2032) & (k units) Table 180. Middle East and Africa Chagas Disease Drug Sales Market Share Forecast by Country (2027-2032) Table 181. Middle East and Africa Chagas Disease Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Middle East and Africa Chagas Disease Drug Market Size by Country (2021-2026) & (US$ Million) Table 183. Middle East and Africa Chagas Disease Drug Market Share by Country (2021-2026) Table 184. Middle East and Africa Chagas Disease Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Middle East and Africa Chagas Disease Drug Market Share Forecast by Country (2027-2032) Table 186. Key Raw Materials Table 187. Raw Materials Key Suppliers Table 188. Chagas Disease Drug Distributors List Table 189. Chagas Disease Drug Customers List Table 190. Research Programs/Design for This Report Table 191. Authors List of This Report Table 192. Secondary Sources Table 193. Primary Sources List of Figures Figure 1. Chagas Disease Drug Image Figure 2. Global Chagas Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chagas Disease Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Chagas Disease Drug Sales (2021-2032) & (k units) Figure 5. Cz-007 Image Figure 6. Global Cz-007 Sales YoY Growth (2021-2032) & (k units) Figure 7. Cz-008 Image Figure 8. Global Cz-008 Sales YoY Growth (2021-2032) & (k units) Figure 9. D-121 Image Figure 10. Global D-121 Sales YoY Growth (2021-2032) & (k units) Figure 11. DNDI-0690 Image Figure 12. Global DNDI-0690 Sales YoY Growth (2021-2032) & (k units) Figure 13. EPLBS-1246 Image Figure 14. Global EPLBS-1246 Sales YoY Growth (2021-2032) & (k units) Figure 15. EPLBS-967 Image Figure 16. Global EPLBS-967 Sales YoY Growth (2021-2032) & (k units) Figure 17. Others Image Figure 18. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 19. Global Chagas Disease Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 20. Global Chagas Disease Drug Market Share by Type 2025 VS 2032 Figure 21. North America Chagas Disease Drug Sales Market Share in Volume by Type in 2025 Figure 22. North America Chagas Disease Drug Sales Market Share in Value by Type in 2025 Figure 23. Europe Chagas Disease Drug Sales Market Share in Volume by Type in 2025 Figure 24. Europe Chagas Disease Drug Sales Market Share in Value by Type in 2025 Figure 25. Asia-Pacific Chagas Disease Drug Sales Market Share in Volume by Type in 2025 Figure 26. Asia-Pacific Chagas Disease Drug Sales Market Share in Value by Type in 2025 Figure 27. Latin America Chagas Disease Drug Sales Market Share in Volume by Type in 2025 Figure 28. Latin America Chagas Disease Drug Sales Market Share in Value by Type in 2025 Figure 29. Middle East and Africa Chagas Disease Drug Sales Market Share in Volume by Type in 2025 Figure 30. Middle East and Africa Chagas Disease Drug Sales Market Share in Value by Type in 2025 Figure 31. Global Top 5 and 10 Chagas Disease Drug Players Market Share by Revenue in 2025 Figure 32. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Hospital Image Figure 34. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 35. Clinic Image Figure 36. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 39. Global Chagas Disease Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Chagas Disease Drug Market Share by Application 2025 VS 2032 Figure 41. North America Chagas Disease Drug Sales Market Share in Volume by Application in 2025 Figure 42. North America Chagas Disease Drug Sales Market Share in Value by Application in 2025 Figure 43. Europe Chagas Disease Drug Sales Market Share in Volume by Application in 2025 Figure 44. Europe Chagas Disease Drug Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Chagas Disease Drug Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Chagas Disease Drug Sales Market Share in Value by Application in 2025 Figure 47. Latin America Chagas Disease Drug Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Chagas Disease Drug Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Chagas Disease Drug Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Chagas Disease Drug Sales Market Share in Value by Application in 2025 Figure 51. North America Chagas Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. North America Chagas Disease Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Chagas Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Chagas Disease Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Chagas Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Europe Chagas Disease Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Chagas Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Chagas Disease Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Chagas Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Asia-Pacific Chagas Disease Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Chagas Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Chagas Disease Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Chagas Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 64. Latin America Chagas Disease Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Chagas Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Chagas Disease Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Chagas Disease Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 68. Middle East and Africa Chagas Disease Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Chagas Disease Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Chagas Disease Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Chagas Disease Drug Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Chagas Disease Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Cz-007
  • Cz-008
  • D-121
  • DNDI-0690
  • EPLBS-1246
  • EPLBS-967
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Eisai Co Ltd
  • Sanofi
  • Novartis AG
  • GlaxoSmithKline Plc
  • Bayer AG
  • AstraZeneca Plc
  • Oblita Therapeutics BVBA
  • Merck & Co Inc
  • Kancera AB
  • Humanigen Inc
  • Grupo Praxis Pharmaceutical SA
  • Daiichi Sankyo Co Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chagas Disease Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Chagas Disease Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Chagas Disease Drug Market by Type
  6. 1.3.1 Cz-007
  7. 1.3.2 Cz-008
  8. 1.3.3 D-121
  9. 1.3.4 DNDI-0690
  10. 1.3.5 EPLBS-1246
  11. 1.3.6 EPLBS-967
  12. 1.3.7 Others
  13. 1.4 Global Chagas Disease Drug Market Size by Type
  14. 1.4.1 Global Chagas Disease Drug Market Size Overview by Type (2021-2032)
  15. 1.4.2 Global Chagas Disease Drug Historic Market Size Review by Type (2021-2026)
  16. 1.4.3 Global Chagas Disease Drug Forecasted Market Size by Type (2027-2032)
  17. 1.5 Key Regions Market Size by Type
  18. 1.5.1 North America Chagas Disease Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.2 Europe Chagas Disease Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.3 Asia-Pacific Chagas Disease Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.4 South America Chagas Disease Drug Sales Breakdown by Type (2021-2026)
  22. 1.5.5 Middle East and Africa Chagas Disease Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Chagas Disease Drug Industry Trends
  2. 2.2 Chagas Disease Drug Industry Drivers
  3. 2.3 Chagas Disease Drug Industry Opportunities and Challenges
  4. 2.4 Chagas Disease Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Chagas Disease Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Chagas Disease Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Chagas Disease Drug Price (2021-2026)
  4. 3.4 Global Chagas Disease Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chagas Disease Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Chagas Disease Drug Company, Product Type & Application
  7. 3.7 Global Chagas Disease Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chagas Disease Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chagas Disease Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chagas Disease Drug Tier 1, Tier 2, and Tier 3
4 Chagas Disease Drug Regional Status and Outlook
  1. 4.1 Global Chagas Disease Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Chagas Disease Drug Historic Market Size by Region
  3. 4.2.1 Global Chagas Disease Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Chagas Disease Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Chagas Disease Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Chagas Disease Drug Forecasted Market Size by Region
  7. 4.3.1 Global Chagas Disease Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Chagas Disease Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Chagas Disease Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Chagas Disease Drug by Application
  1. 5.1 Chagas Disease Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Chagas Disease Drug Market Size by Application
  6. 5.2.1 Global Chagas Disease Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Chagas Disease Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Chagas Disease Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Chagas Disease Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Chagas Disease Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Chagas Disease Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Chagas Disease Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Chagas Disease Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Eisai Co Ltd
  2. 6.1.1 Eisai Co Ltd Company Information
  3. 6.1.2 Eisai Co Ltd Business Overview
  4. 6.1.3 Eisai Co Ltd Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Eisai Co Ltd Chagas Disease Drug Product Portfolio
  6. 6.1.5 Eisai Co Ltd Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Chagas Disease Drug Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Novartis AG
  14. 6.3.1 Novartis AG Company Information
  15. 6.3.2 Novartis AG Business Overview
  16. 6.3.3 Novartis AG Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novartis AG Chagas Disease Drug Product Portfolio
  18. 6.3.5 Novartis AG Recent Developments
  19. 6.4 GlaxoSmithKline Plc
  20. 6.4.1 GlaxoSmithKline Plc Company Information
  21. 6.4.2 GlaxoSmithKline Plc Business Overview
  22. 6.4.3 GlaxoSmithKline Plc Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 GlaxoSmithKline Plc Chagas Disease Drug Product Portfolio
  24. 6.4.5 GlaxoSmithKline Plc Recent Developments
  25. 6.5 Bayer AG
  26. 6.5.1 Bayer AG Company Information
  27. 6.5.2 Bayer AG Business Overview
  28. 6.5.3 Bayer AG Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Bayer AG Chagas Disease Drug Product Portfolio
  30. 6.5.5 Bayer AG Recent Developments
  31. 6.6 AstraZeneca Plc
  32. 6.6.1 AstraZeneca Plc Company Information
  33. 6.6.2 AstraZeneca Plc Business Overview
  34. 6.6.3 AstraZeneca Plc Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 AstraZeneca Plc Chagas Disease Drug Product Portfolio
  36. 6.6.5 AstraZeneca Plc Recent Developments
  37. 6.7 Oblita Therapeutics BVBA
  38. 6.7.1 Oblita Therapeutics BVBA Company Information
  39. 6.7.2 Oblita Therapeutics BVBA Business Overview
  40. 6.7.3 Oblita Therapeutics BVBA Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Oblita Therapeutics BVBA Chagas Disease Drug Product Portfolio
  42. 6.7.5 Oblita Therapeutics BVBA Recent Developments
  43. 6.8 Merck & Co Inc
  44. 6.8.1 Merck & Co Inc Company Information
  45. 6.8.2 Merck & Co Inc Business Overview
  46. 6.8.3 Merck & Co Inc Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Merck & Co Inc Chagas Disease Drug Product Portfolio
  48. 6.8.5 Merck & Co Inc Recent Developments
  49. 6.9 Kancera AB
  50. 6.9.1 Kancera AB Company Information
  51. 6.9.2 Kancera AB Business Overview
  52. 6.9.3 Kancera AB Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Kancera AB Chagas Disease Drug Product Portfolio
  54. 6.9.5 Kancera AB Recent Developments
  55. 6.10 Humanigen Inc
  56. 6.10.1 Humanigen Inc Company Information
  57. 6.10.2 Humanigen Inc Business Overview
  58. 6.10.3 Humanigen Inc Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Humanigen Inc Chagas Disease Drug Product Portfolio
  60. 6.10.5 Humanigen Inc Recent Developments
  61. 6.11 Grupo Praxis Pharmaceutical SA
  62. 6.11.1 Grupo Praxis Pharmaceutical SA Company Information
  63. 6.11.2 Grupo Praxis Pharmaceutical SA Business Overview
  64. 6.11.3 Grupo Praxis Pharmaceutical SA Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Grupo Praxis Pharmaceutical SA Chagas Disease Drug Product Portfolio
  66. 6.11.5 Grupo Praxis Pharmaceutical SA Recent Developments
  67. 6.12 Daiichi Sankyo Co Ltd
  68. 6.12.1 Daiichi Sankyo Co Ltd Company Information
  69. 6.12.2 Daiichi Sankyo Co Ltd Business Overview
  70. 6.12.3 Daiichi Sankyo Co Ltd Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Daiichi Sankyo Co Ltd Chagas Disease Drug Product Portfolio
  72. 6.12.5 Daiichi Sankyo Co Ltd Recent Developments
7 North America by Country
  1. 7.1 North America Chagas Disease Drug Sales by Country
  2. 7.1.1 North America Chagas Disease Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Chagas Disease Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Chagas Disease Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Chagas Disease Drug Market Size by Country
  6. 7.2.1 North America Chagas Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Chagas Disease Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Chagas Disease Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Chagas Disease Drug Sales by Country
  2. 8.1.1 Europe Chagas Disease Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Chagas Disease Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Chagas Disease Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Chagas Disease Drug Market Size by Country
  6. 8.2.1 Europe Chagas Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Chagas Disease Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Chagas Disease Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Chagas Disease Drug Sales by Country
  2. 9.1.1 Asia-Pacific Chagas Disease Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Chagas Disease Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Chagas Disease Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Chagas Disease Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Chagas Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Chagas Disease Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Chagas Disease Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Chagas Disease Drug Sales by Country
  2. 10.1.1 South America Chagas Disease Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Chagas Disease Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Chagas Disease Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Chagas Disease Drug Market Size by Country
  6. 10.2.1 South America Chagas Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Chagas Disease Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Chagas Disease Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Chagas Disease Drug Sales by Country
  2. 11.1.1 Middle East and Africa Chagas Disease Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Chagas Disease Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Chagas Disease Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Chagas Disease Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Chagas Disease Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Chagas Disease Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Chagas Disease Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Chagas Disease Drug Value Chain Analysis
  2. 12.1.1 Chagas Disease Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Chagas Disease Drug Production Mode & Process
  7. 12.2 Chagas Disease Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Chagas Disease Drug Distributors
  10. 12.2.3 Chagas Disease Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst